Literature DB >> 563462

Structural requirements for antileukemic activity among the naturally occurring and semisynthetic maytansinoids.

S M Kupchan, A T Sneden, A R Branfman, G A Howie, L I Rebhun, W E McIvor, R W Wang, T C Schnaitman.   

Abstract

In an effort to determine the structural requirements for the significant antileukemic, cytotoxic, antitubulin, and antimitotic activity exhibited by the novel ansa macrolide, maytansine (1), four new C-3 ester and six new C-9 ether homologues were synthesized. The biological activities of these compounds were assayed and compared to the activities of previously reported, naturally occurring maytansinoids. From the data, it is apparent that presence of the C-3 ester is necessary for significant activity, and variations in the ester group are not accompanied by marked changes in activity. However, elimination of the ester group, as in maytansinol (7), maysine (8), normaysine (9), and maysenine (10), results in a significant decrease in biological activity. Blockage of the C-9 carbinolamide via etherification markedly reduces antileukemic and cytotoxic activity and slightly reduces antitubulin activity but has relatively little effect on antimitotic activity against sea urchin eggs. Thus, a free carbinolamide at C-9 is advantageous for optimal activity.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 563462     DOI: 10.1021/jm00199a006

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  11 in total

Review 1.  Plant-derived natural product research aimed at new drug discovery.

Authors:  Hideji Itokawa; Susan L Morris-Natschke; Toshiyuki Akiyama; Kuo-Hsiung Lee
Journal:  J Nat Med       Date:  2008-04-22       Impact factor: 2.343

Review 2.  Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.

Authors:  Satish K Singh; Donna L Luisi; Roger H Pak
Journal:  Pharm Res       Date:  2015-05-19       Impact factor: 4.200

3.  Structure-activity relationships among maytansinoids in their effect on the European corn borer,Ostrinia nubilalis (Hübner).

Authors:  R V Madrigal; B W Zilkowski; C R Smith
Journal:  J Chem Ecol       Date:  1985-04       Impact factor: 2.626

4.  Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability.

Authors:  Emin Oroudjev; Manu Lopus; Leslie Wilson; Charlene Audette; Carmela Provenzano; Hans Erickson; Yelena Kovtun; Ravi Chari; Mary Ann Jordan
Journal:  Mol Cancer Ther       Date:  2010-10       Impact factor: 6.261

5.  The biosynthetic gene cluster of the maytansinoid antitumor agent ansamitocin from Actinosynnema pretiosum.

Authors:  Tin-Wein Yu; Linquan Bai; Dorothee Clade; Dietmar Hoffmann; Sabine Toelzer; Khue Q Trinh; Jun Xu; Steven J Moss; Eckhard Leistner; Heinz G Floss
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-11       Impact factor: 11.205

Review 6.  Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components.

Authors:  Franco Dosio; Paola Brusa; Luigi Cattel
Journal:  Toxins (Basel)       Date:  2011-07-14       Impact factor: 4.546

7.  Ansamitocin P3 depolymerizes microtubules and induces apoptosis by binding to tubulin at the vinblastine site.

Authors:  Jubina B Venghateri; Tilak Kumar Gupta; Paul J Verma; Ambarish Kunwar; Dulal Panda
Journal:  PLoS One       Date:  2013-10-04       Impact factor: 3.240

Review 8.  Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.

Authors:  John M Lambert; Charles Q Morris
Journal:  Adv Ther       Date:  2017-03-30       Impact factor: 3.845

Review 9.  Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.

Authors:  Hao Chen; Zongtao Lin; Kinsie E Arnst; Duane D Miller; Wei Li
Journal:  Molecules       Date:  2017-08-01       Impact factor: 4.411

10.  Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001.

Authors:  Cristina L Abrahams; Xiaofan Li; Millicent Embry; Abigail Yu; Stellanie Krimm; Sarah Krueger; Nancy Y Greenland; Kwun Wah Wen; Chris Jones; Venita DeAlmeida; Willy A Solis; Shannon Matheny; Toni Kline; Alice Y Yam; Ryan Stafford; Arun P Wiita; Trevor Hallam; Mark Lupher; Arturo Molina
Journal:  Oncotarget       Date:  2018-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.